Show simple item record

dc.contributor.authorWHO
dc.date.accessioned2020-07-02T07:38:06Z
dc.date.available2020-07-02T07:38:06Z
dc.date.issued2017-03
dc.identifier.urihttp://dspace.ceid.org.tr/xmlui/handle/1/564
dc.description.abstractThe core list presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost–effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive costeffectiveness in a variety of settings. The square box symbol () is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Not all square boxes are applicable to medicine selection for children — see the second EMLc for details.en_US
dc.language.isoenen_US
dc.publisherWorld Health Organizationen_US
dc.subjectSağlık hizmetlerien_US
dc.subjectHealth Serviceen_US
dc.titleWHO Model List of Essential Medicinesen_US
dc.typeBirleşmiş Milletler Raporuen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record